4D Molecular Therapeutics (FDMT) Competitors $6.32 -0.16 (-2.47%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FDMT vs. CALT, SPRY, SNDX, ANIP, RCKT, BCYC, AVDL, SEPN, COLL, and BCAXShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Septerna (SEPN), Collegium Pharmaceutical (COLL), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Calliditas Therapeutics AB (publ) ARS Pharmaceuticals Syndax Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Septerna Collegium Pharmaceutical Bicara Therapeutics 4D Molecular Therapeutics (NASDAQ:FDMT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Does the MarketBeat Community prefer FDMT or CALT? 4D Molecular Therapeutics received 21 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 70.59% of users gave 4D Molecular Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperform4D Molecular TherapeuticsOutperform Votes4870.59% Underperform Votes2029.41% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Is FDMT or CALT more profitable? 4D Molecular Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. 4D Molecular Therapeutics' return on equity of -28.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular TherapeuticsN/A -28.00% -26.16% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the media prefer FDMT or CALT? In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). 4D Molecular Therapeutics' average media sentiment score of 0.27 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Overall Sentiment 4D Molecular Therapeutics Neutral Calliditas Therapeutics AB (publ) Neutral Which has more risk & volatility, FDMT or CALT? 4D Molecular Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Do insiders & institutionals believe in FDMT or CALT? 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, FDMT or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than 4D Molecular Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$17K17,185.94-$100.84M-$2.85-2.22Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Do analysts prefer FDMT or CALT? 4D Molecular Therapeutics presently has a consensus target price of $42.13, indicating a potential upside of 566.53%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, indicating a potential downside of 1.88%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Summary4D Molecular Therapeutics beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.56M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-2.2247.02135.1917.53Price / Sales17,185.94420.131,224.59140.21Price / CashN/A182.1340.6537.95Price / Book0.883.924.884.92Net Income-$100.84M-$42.03M$118.97M$225.78M7 Day Performance-8.41%-3.37%15.53%-1.58%1 Month Performance-24.04%7.95%15.54%6.67%1 Year Performance-66.26%21.00%34.63%22.48% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.7235 of 5 stars$6.32-2.5%$42.13+566.5%-64.4%$299.56M$17,000.00-2.22201Analyst ForecastShort Interest ↑CALTCalliditas Therapeutics AB (publ)N/A$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.067 of 5 stars$12.12+1.8%$24.00+98.0%+125.7%$1.18B$30,000.00-23.3390SNDXSyndax Pharmaceuticals3.9667 of 5 stars$13.76-1.2%$37.64+173.5%-34.4%$1.17B$16M-3.84110ANIPANI Pharmaceuticals4.8134 of 5 stars$55.69-1.6%$77.71+39.5%+5.5%$1.17B$555.46M-102.89642Short Interest ↓RCKTRocket Pharmaceuticals4.8536 of 5 stars$12.00-0.2%$51.00+325.0%-57.9%$1.09BN/A-4.37240Analyst ForecastAnalyst RevisionBCYCBicycle Therapeutics3.5654 of 5 stars$15.31+10.9%$36.00+135.1%-13.5%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeHigh Trading VolumeAVDLAvadel Pharmaceuticals2.7929 of 5 stars$10.90+4.9%$24.43+124.1%-23.3%$1.05B$138.16M-13.15154Short Interest ↑SEPNSepterna1.7246 of 5 stars$22.24-0.7%$43.67+96.3%N/A$987.46MN/A0.00N/ACOLLCollegium Pharmaceutical3.9352 of 5 stars$30.55+1.5%$42.60+39.4%+4.3%$985.24M$599.25M12.97210News CoveragePositive NewsBCAXBicara TherapeuticsN/A$17.57+0.4%$43.00+144.7%N/A$956.09MN/A0.0032 Related Companies and Tools Related Companies CALT Alternatives SPRY Alternatives SNDX Alternatives ANIP Alternatives RCKT Alternatives BCYC Alternatives AVDL Alternatives SEPN Alternatives COLL Alternatives BCAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FDMT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
